# Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

> **NCT00809211** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 40 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** nilotinib
- **GENETIC:** cytogenetic analysis
- **GENETIC:** mutation analysis
- **GENETIC:** polymerase chain reaction
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00809211
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-05
- **Final completion:** 2016-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00809211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00809211, "Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00809211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*